Opinion|Videos|July 15, 2024
Dr Locke Shares Key Takeaways from ZUMA-7 and TRANSFORM Studies
An examination of results from key studies in the DLBCL landscape are conducted by Dr Fred Locke.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please discuss the data supporting CAR T-cell therapy as the primary 2Ltreatment option for patients who are transplant-eligible and have primary refractory or early relapse R/R DLBCL.
- Please review the latest 56-month follow-up data of the ZUMA-7study, evaluating axi-cel.
- ASH 2024 Update: Subgroup Analysis of the ZUMA-7 study.
- Please discuss the subsequent cellular immunotherapy off-protocol in the SOC arm.
- Please review the latest 56-month follow-up data of the ZUMA-7study, evaluating axi-cel.
- Please review the 36-month follow-up data of the TRANSFORM study, evaluating liso-cel.
- ASCO 2024 Update: Subgroup analysis of the TRANSFORM study [primary refractory vs. early relapsed].
- What were some key takeaways from the results of these two studies?
Advertisement
Related to this article
Teclistamab plus talquetamab met the primary PFS end point and improved overall survival in relapsed/refractory multiple myeloma in MonumenTAL-6.
The FDA has granted priority review to a supplemental application for talazoparib plus enzalutamide in HRR-altered mCSPC.
Camizestrant plus a CDK4/6 inhibitor was approved in the European Union for ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.
The FDA is reviewing data for daraxonrasib in previously treated pancreatic cancer under the Commissioner’s National Priority Voucher program.
Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.
Matthew Galsky, MD, discusses the FDA approval of perioperative pembrolizumab plus enfortumab vedotin in MIBC.
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
A 3-year, $225K award will focus on improving quality of life for patients living with long-term effects of cancer treatment.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
3
Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer
4
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
5